Patient characteristics at registration
. | No. of patients (% of 292) . |
|---|---|
| Sex | |
| Male | 160 (55) |
| Female | 132 (45) |
| Age, y | |
| Median | 43 |
| Range | 15-60 |
| Younger than 20 | 18 (6) |
| 20-29 | 52 (18) |
| 30-39 | 59 (20) |
| 40-49 | 70 (24) |
| 50-60 | 93 (32) |
| ECOG performance status | |
| 0 | 147 (50) |
| 1 | 113 (39) |
| 2 | 23 (8) |
| 3 | 9 (3) |
| FAB classification, institutional | |
| M0 | 18 (6) |
| M1 | 41 (14) |
| M2 | 97 (33) |
| M4 | 75 (26) |
| M5 | 40 (14) |
| M6 | 6 (2) |
| M7 | 9 (3) |
| Biphenotypic M4, M6 | 1 (0) |
| Unknown | 5 (2) |
| WCC at diagnosis | |
| At least 100 × 109/L | 29 (10) |
| Clinical bleeding | |
| None | 226 (77) |
| Petechiae | 25 (9) |
| Mild blood loss | 39 (13) |
| Gross | 2 (1) |
| Febrile at time of registration | |
| Yes | 84 (29) |
| Cytogenetic risk group | |
| Favorable | 42 (14) |
| Intermediate | 211 (72) |
| Adverse | 21 (7) |
| Unknown | 18 (6) |
. | No. of patients (% of 292) . |
|---|---|
| Sex | |
| Male | 160 (55) |
| Female | 132 (45) |
| Age, y | |
| Median | 43 |
| Range | 15-60 |
| Younger than 20 | 18 (6) |
| 20-29 | 52 (18) |
| 30-39 | 59 (20) |
| 40-49 | 70 (24) |
| 50-60 | 93 (32) |
| ECOG performance status | |
| 0 | 147 (50) |
| 1 | 113 (39) |
| 2 | 23 (8) |
| 3 | 9 (3) |
| FAB classification, institutional | |
| M0 | 18 (6) |
| M1 | 41 (14) |
| M2 | 97 (33) |
| M4 | 75 (26) |
| M5 | 40 (14) |
| M6 | 6 (2) |
| M7 | 9 (3) |
| Biphenotypic M4, M6 | 1 (0) |
| Unknown | 5 (2) |
| WCC at diagnosis | |
| At least 100 × 109/L | 29 (10) |
| Clinical bleeding | |
| None | 226 (77) |
| Petechiae | 25 (9) |
| Mild blood loss | 39 (13) |
| Gross | 2 (1) |
| Febrile at time of registration | |
| Yes | 84 (29) |
| Cytogenetic risk group | |
| Favorable | 42 (14) |
| Intermediate | 211 (72) |
| Adverse | 21 (7) |
| Unknown | 18 (6) |
ECOG indicates Eastern Cooperative Oncology Group; FAB, French-American-British; M, FAB classification code denoting myeloid leukemia; and WCC, white cell count.